Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Safe Supply Announces Signing of Definitive Agreement to Acquire Drug Lab 118 (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Grace Therapeutics, Inc GRCE

Healthcare
Grace Therapeutics, Inc., formerly Acasti Pharma Inc., is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its therapeutic pipeline consists of three clinical-stage drug candidates supported by an intellectual property portfolio of over 40 granted and pending patents in various jurisdictions. Its lead drug candidate, GTX-104, is a clinical-stage, novel... see more

NDAQ:GRCE - Post Discussion

Grace Therapeutics, Inc > Matinas byte the dust vs Vascepa ...
View:
Post by Francine01 on Feb 01, 2021 12:03pm

Matinas byte the dust vs Vascepa ...

This morning another failed with Matinas vs Vascepa. 

Acasti managemetnt is silent, it would be interesting to know what are they views for Capre in the actual context. 

Another point, MTNB shared trial all the secondary end points. I am still puzzled why Acasti, after 5 month +, did not share the secondary end points. It seems that they are hiding information to shareholders... 

GLTA
Comment by EternalPonzi on Feb 02, 2021 12:36am
</br secondaries yielded nothing. thus the silence. company is a fraud. if it wasn't for the atm financing i'd short the $&-t out of this useless company and ride it all the way down to its rightful price of zero. it must be nice to be able to to produce absolutely nothing, communicate nothing of consequence and still make hundresds of thousands of dollars salary not to mention ...more  
Grace Therapeutics, Inc
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Dealroom for high-potential pre-IPO opportunities